Exosomes and stem cell products are marketed hard in aesthetics — for hair, skin, joints and “regeneration” generally. They are also among the most consistently enforced-against categories in the sector.
The reason is structural rather than a matter of opinion: these products are generally regulated as biological drugs, and none of the exosome products circulating in aesthetics is FDA approved.
How the regulation works
Human cells, tissues, and cellular and tissue-based products sit in a framework that turns on how minimally they are handled and whether they are used for the same basic function they served in the donor.
Products meeting narrow criteria are regulated with lighter requirements. Products that fall outside them — because they are more than minimally manipulated, or promoted for a different function than they performed in the donor — are regulated as drugs or biological products, which means they require FDA approval before marketing.
Injecting an exosome preparation to regenerate tissue or restore hair growth is a use that generally falls outside the narrow criteria. That places it in drug territory, and there is no approval.
The claims are usually the trigger
Enforcement in this area frequently starts with marketing. A clinic’s own website establishes what the product is intended to do, and intended use is what determines how a product is regulated.
Language that reliably draws attention:
- “Regenerate”, “repair”, “restore”, “reverse”
- Naming conditions — arthritis, hair loss, neuropathy, autoimmune disease
- “Stem cell therapy” for anything other than an approved indication
- “FDA registered” applied to a facility as though it validated the product
- Before-and-after imagery implying a therapeutic outcome
- Patient testimonials describing conditions treated
A practice can create its own regulatory problem purely through copywriting, with no change to what is in the vial.
Safety is a real issue, not a technicality
These are injected products that are not manufactured under the controls approved biologics require. Sterility, potency, identity and contamination are not assured, and there have been documented adverse event clusters associated with unapproved regenerative products.
The compliance argument and the patient-safety argument point the same direction here, which is not always true.
What operators tell themselves
| The rationalisation | Why it does not hold |
|---|---|
| “The supplier says it is FDA registered” | Facility registration is an administrative filing; it says nothing about product approval |
| “It is a cosmetic, not a drug” | Intended use determines classification, and regeneration claims are not cosmetic claims |
| “We only use it topically” | Topical application after microneedling is not the same as topical cosmetic use; the claim still governs |
| “Patients sign a consent” | Consent does not make an unapproved product lawful to market or administer |
| “Everyone in town offers it” | Enforcement is not a defence based on prevalence |
If you are being offered these products
- Ask whether the product has FDA approval or a licensed biologics application. Ask for the number.
- Ask under what regulatory framework the supplier believes it is marketed.
- Ask whether the supplier has received FDA correspondence about it.
- Read your malpractice policy on unapproved products before you assume you are covered.
The answers are usually vague, and the vagueness is the information.
The certification dimension
If you hold a healthcare merchant certification, marketing unapproved biologics with therapeutic claims is squarely the kind of thing that puts it at risk — and losing it can affect payment processing and advertising eligibility, which hurts more immediately than a regulatory letter.
Where MDside stands
Our protocols do not permit administering unapproved biological products, and we review the clinical claims on the pages our practices publish, because intended use is established by marketing as much as by anything else.
See what is included, or read what “FDA approved” actually means.
Frequently asked questions
Are exosome products FDA approved?
No exosome product is approved for the aesthetic and regenerative uses marketed in this sector. Products promoted for those purposes are generally regulated as biological drugs requiring approval.
Does “FDA registered facility” mean the product is legal?
No. Registration is an administrative filing about a facility. It carries no finding about a product’s safety, effectiveness, or approval status.
Can I use exosomes topically after microneedling?
Applying a product to skin breached by microneedling is not ordinary topical cosmetic use, and the claims made about it still determine how it is regulated. This is a common workaround that does not work.
What if the patient requests it specifically?
Patient demand does not change a product’s regulatory status, and consent does not authorise administering an unapproved biologic.
Does my malpractice policy cover unapproved biologics?
Do not assume so. Carriers are not obliged to defend the administration of unapproved products, and some policies exclude it explicitly. Read the policy before you offer the service, not after an adverse event.
General information about biologics regulation, not legal or clinical advice. Confirm any product’s regulatory status directly and consult healthcare counsel before offering regenerative products.